At ISC 2026, a 20-minute IP-RPLC–UV assay distinguished mRNA capping variants without mass spectrometry, matching a UHPLC–MS reference method.
|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
Clinical Trial Sponsors Face Growing Regulatory Burden
Safety and ethical concerns generate additional reporting and disclosure policies despite efforts to streamline research requirements.
Advertisement
Articles in this issue
about 20 years ago
Analytical Instrument Qualificationabout 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?about 20 years ago
Team Effortabout 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedabout 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionabout 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressabout 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefabout 20 years ago
New Climateabout 20 years ago
2006: A Regulatory OdysseyAdvertisement
Related to this article
Advertisement
Advertisement